Biogen Pharmachem Industries (531752) Q4 14/15 earnings summary

Executive summary

• No business activity during FY15 amid financial constraints; operating revenue was nil and net loss was ₹1,327,795.

• Management cited scarce working capital, pursued cost reductions, and said future development depended on restarting operations.

Financial highlights

• Revenue from operations was nil; other income was ₹35,090, comprising dividend income, versus nil total revenue in FY14.

• Net loss was ₹1,327,795 in FY15 versus ₹1,301,411 in FY14; total expenses were ₹1,362,885.

• Paid-up equity capital remained ₹652,603,000; reserves and surplus were negative ₹42,712,540 at year-end.

• Auditors reported cash losses of ₹223,734 in FY15 and losses in the preceding year.

Outlook and guidance

• Future development depended on resuming operations; management was seeking an opportunity to make operations functional and pursuing feasible cost cuts.